What insurance policy changes affect CPT 84999?

There are 10 tracked policy changes affecting CPT 84999, including updates from Humana, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 84999?

Payers that have issued tracked updates for CPT 84999 include: Humana, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 84999 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 84999. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 84999?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

84999 Insurance Policy Changes

CPT 84999 is referenced in 10 tracked payer policy changes from Humana and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 84999 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact
Molecular Diagnostic Assays and Breath Testing for Transplant Rejection - MEDICAID - KENTUCKY (Revised)
Humana·Effective Nov 12, 2025
Humana Kentucky Medicaid will not cover any molecular diagnostic assays or breath testing for transplant rejection effective November 12, 2025. All related testing including gene expression profiling, donor-derived cell-free DNA tests, and HLA testing for rejection monitoring are excluded from coverage.
Medium impact
Gene Expression Profiling for Cutaneous Melanoma
Blue Cross & Blue Shield of Mississippi·Effective Oct 1, 2025
This policy update declares all gene expression profiling tests for melanoma evaluation as investigational and non-covered, including specific tests like Pigmented Lesion Assay, myPath Melanoma, and DecisionDx-Melanoma. A new CPT code 0578U was added effective 10/01/2025 for a melanoma gene expression test, but it remains investigational.
Medium impact
Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
BCBS Mississippi considers serum biomarker panel testing with proprietary algorithms for diagnosing systemic lupus erythematosus and other connective tissue diseases as investigational and not covered. This affects specific laboratory tests including Avise tests and related CPT codes that will be denied if billed.
Medium impact
Nutrient/Nutritional Panel Testing
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This policy confirms that nutrient/nutritional panel testing (including NutrEval FMV, NutrEval Plasma, and SpectraCell micronutrient tests) remains considered investigational for all indications. Claims using the specified CPT codes for these comprehensive nutritional panels will be denied as not medically necessary.
Low impact
Serum Holo-Transcobalamin as a Marker of Vitamin B12 (i.e., Cobalamin) Status
Blue Cross & Blue Shield of Mississippi·Effective Aug 4, 2025
This policy confirms that serum holotranscobalamin testing for Vitamin B12 deficiency diagnosis remains investigational and non-covered. The policy was recently reviewed with updated sources but no coverage changes were made.
Low impact
KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy
Blue Cross & Blue Shield of Mississippi·Effective Aug 1, 2025
KIF6 genotyping for cardiovascular risk prediction and statin therapy effectiveness remains classified as investigational and not covered. This policy was reviewed with no changes as of August 1, 2025.
Low impact
Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease
Blue Cross & Blue Shield of Mississippi·Effective Jul 31, 2025
This policy confirms that gene expression testing for stable ischemic heart disease evaluation remains investigational and non-covered. The policy was recently reviewed with no changes, maintaining that these tests are not considered medically necessary.
Low impact
Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With Cancer
Blue Cross & Blue Shield of Mississippi·Effective Apr 17, 2025
This policy confirms that laboratory testing for 5-fluorouracil dosing optimization (area under curve analysis) and genetic testing for DPYD/TYMS gene variants to guide 5-fluorouracil chemotherapy dosing remain investigational and not covered. No changes were made to the existing policy.
Low impact
Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or Aneurysm
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This policy confirms that genotyping for 9p21 single nucleotide polymorphisms to predict cardiovascular disease or aneurysm risk remains investigational and non-covered. The policy was reviewed on 07/31/2025 with no changes to the investigational status.
Low impact
Analysis of Proteomic Patterns for Early Detection of Cancer
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
This policy confirms that proteomic pattern analysis tests for early cancer detection (including ovarian and prostate cancer screening) remain classified as investigational and are not covered. The policy has not changed from previous versions and continues to exclude coverage for these tests.

All billing codes J3590 99213 99214 99212 99202 99203

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Molecular Diagnostic Assays and Breath Testing for Transplant Rejection - MEDICAID - KENTUCKY (Revised)

Gene Expression Profiling for Cutaneous Melanoma

Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases

Nutrient/Nutritional Panel Testing

Serum Holo-Transcobalamin as a Marker of Vitamin B12 (i.e., Cobalamin) Status

KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy

Gene Expression Testing in the Evaluation of Patients with Stable Ischemic Heart Disease

Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With Cancer

Genotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or Aneurysm

Analysis of Proteomic Patterns for Early Detection of Cancer